Icon Plc (NASDAQ:ICLR) has earned a consensus recommendation of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $151.44.
ICLR has been the topic of a number of research reports. BidaskClub downgraded Icon from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 20th. Goldman Sachs Group downgraded Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 target price on the stock. in a report on Friday, December 14th. Zacks Investment Research downgraded Icon from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Mizuho upgraded Icon from a “neutral” rating to a “buy” rating and upped their target price for the company from $146.00 to $150.00 in a report on Friday, January 25th. Finally, Barclays boosted their price target on Icon from $130.00 to $140.00 and gave the company an “equal weight” rating in a research note on Thursday, February 21st.
Shares of ICLR traded up $2.42 during trading hours on Friday, reaching $134.65. The company’s stock had a trading volume of 13,720 shares, compared to its average volume of 313,399. The company has a market capitalization of $7.11 billion, a price-to-earnings ratio of 21.45, a P/E/G ratio of 1.65 and a beta of 0.66. Icon has a 1-year low of $110.21 and a 1-year high of $155.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.18 and a quick ratio of 2.18.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in shares of Icon by 10.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 164,947 shares of the medical research company’s stock valued at $21,860,000 after buying an additional 15,137 shares in the last quarter. Man Group plc grew its stake in shares of Icon by 40.0% in the 3rd quarter. Man Group plc now owns 72,673 shares of the medical research company’s stock valued at $11,174,000 after buying an additional 20,778 shares in the last quarter. Blackcrane Capital LLC bought a new stake in shares of Icon in the 4th quarter valued at approximately $19,576,000. Morgan Stanley boosted its position in Icon by 41.4% during the third quarter. Morgan Stanley now owns 82,894 shares of the medical research company’s stock worth $12,745,000 after purchasing an additional 24,256 shares during the period. Finally, Marshall Wace LLP bought a new stake in Icon during the third quarter worth approximately $3,700,000. 86.41% of the stock is owned by institutional investors and hedge funds.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More: What are the FAANG Stocks?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.